Clinical Trial Update: A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause [Phase 3]

View source ↗

Summary

Phase 3 long-term safety trial of fezolinetant for menopausal hot flashes has completed and posted results on February 1, 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Menopause

Drugs mentioned

• Fezolinetant (fezolinetant)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Hot Flashes | Phase 3 | Status: COMPLETED | Results posted: 2023-02-01